Krystal Biotech Inc. (KRYS) is a clinical-stage biotechnology company focused on the development and commercialization of gene therapies for the treatment of rare genetic diseases. The company's lead product candidate is KB103, a topical gene therapy for the treatment of dystrophic epidermolysis bullosa (DEB), a rare genetic skin disease that can cause severe blistering and skin erosion. KB103 is designed to deliver a functional copy of the COL7A1 gene to the skin cells of DEB patients, with the aim of improving skin integrity and reducing the severity of the disease. Krystal Biotech is also developing gene therapies for other rare genetic diseases, including KB105 for patients with TGM1-deficient autosomal recessive congenital ichthyosis (ARCI). The company is based in Pittsburgh, Pennsylvania. As of September 2021, Krystal Biotech had a market capitalization of approximately $2.28 billion.
Krystal Biotech Inc. (KRYS) is a clinical-stage biotechnology company focused on the development and commercialization of gene therapies for the treatment of rare genetic diseases. The company's lead product candidate is KB103, a topical gene therapy for the treatment of dystrophic epidermolysis bullosa (DEB), a rare genetic skin disease that can cause severe blistering and skin erosion. KB103 is designed to deliver a functional copy of the COL7A1 gene to the skin cells of DEB patients, with the aim of improving skin integrity and reducing the severity of the disease. Krystal Biotech is also developing gene therapies for other rare genetic diseases, including KB105 for patients with TGM1-deficient autosomal recessive congenital ichthyosis (ARCI). The company is based in Pittsburgh, Pennsylvania. As of September 2021, Krystal Biotech had a market capitalization of approximately $2.28 billion.